San Francisco, CA | September 1–10, 2026: hubXchange today announced its San Francisco Life Science Roundtable Series, bringing together senior scientists, executives and C-suite industry leaders from across pharmaceutical and biotechnology organisations for six discussion-led Xchanges focused on some of the most important challenges in drug discovery, development and manufacturing.

Taking place at the DoubleTree by Hilton San Francisco Airport Hotel, the 2026 series will feature six highly curated, complimentary-to-attend, one-day meetings.

Each event is designed to maximise peer-level interaction through expert-led roundtable discussions, scientific presentations, poster sessions, pre-scheduled 1:1 meetings and structured networking opportunities.

San Francisco Life Science Roundtable Series 2026 – Event Line-Up

• Antibody CMC Development Xchange

Tuesday, September 1, 2026

Addressing challenges across cell line development, upstream development, downstream processing and purification, formulation and stability, and quality control and characterisation.  Topics will include the development and manufacturing of complex biologics, multispecific expression, viral inactivation, host-cell protein contamination, formulation strategies and long-term stability prediction.

• Antibody Therapeutics Xchange

Wednesday, September 2, 2026

Advancing next-generation antibodies, bispecific and multispecific therapeutics, ADCs and emerging antibody formats from target selection through lead optimisation and early development.

Discussions will explore target selection and mechanisms of action, lead identification and optimisation, formats and scaffolds, bi- and multispecifics, ADC linker design and conjugation technologies, and cytotoxic payload development.

• Oligonucleotide & Peptides Xchange

Thursday, September 3, 2026

Exploring the scientific, delivery, development and manufacturing challenges shaping the next generation of oligonucleotide and peptide therapeutics.

The programme will focus on novel modalities and discovery, drug delivery, CMC and process development, and quality control.

• Advanced Therapies Xchange

Tuesday, September 8, 2026

Focused on the development and manufacture of cell and gene therapies, next-generation vectors and enabling delivery technologies.

Roundtable discussions will address next-generation vector engineering and delivery, cell therapy development, gene therapy development, cell therapy manufacturing and gene therapy manufacturing.

• AI in Drug Discovery Xchange

Wednesday, September 9, 2026

Examining how artificial intelligence and machine learning can be applied across pharmaceutical research and development to improve scientific decision-making and accelerate the discovery of new medicines.

The agenda will cover data quality, target identification, lead generation and optimisation, drug-response prediction, and drug design and modelling.

• CNS Therapeutics Xchange

Thursday, September 10, 2026

Tackling the scientific and translational challenges limiting success in neuroscience research and CNS drug development.

Discussions will focus on target discovery, biomarkers, blood–brain barrier strategies, preclinical models and clinical development.

Each roundtable Xchange is invitation-only and intentionally capped to maintain seniority, relevance and meaningful scientific exchange. Complimentary registration is available for senior-level scientists and executives from pharmaceutical and biotechnology companies with an active drug pipeline.

To secure your complimentary pass: https://hub-xchange.com/xchanges-topic#SanFrancisco 

Leadership Commentary

Clarence Maguire-Swartz, Founder and Managing Director of hubXchange, commented:

“San Francisco and the wider Bay Area continue to play a central role in global life sciences innovation. The region brings together pioneering biotechnology companies, established pharmaceutical organisations, leading research institutions and an active investment community. Our roundtable Xchange model is designed to move beyond the traditional large-scale conference format by creating a more focused environment where senior decision-makers can have honest, technical discussions about the challenges they are facing.

Through small, expertly curated roundtables, concise scientific presentations and pre-booked one-to-one meetings, participants can exchange practical insights, establish relevant connections and identify potential solutions that can be applied within their own organisations.”

Nathan Merryfield, Marketing Director at hubXchange, added:

“The San Francisco series represents one of the most comprehensive programmes in our global calendar, covering six closely connected areas of therapeutic research, development and manufacturing. The depth of the agendas, the calibre of the industry experts and the interactive nature of the format continue to resonate with senior scientists and executives who are looking for substantive scientific discussion rather than scale alone. We are looking forward to bringing the community together in September for two weeks of focused conversations, new connections and collaboration across the life sciences.”

About hubXchange

hubXchange designs and delivers closed-door, discussion-led roundtable events, known as Xchanges, for senior leaders across pharmaceutical, biotechnology and adjacent life sciences sectors.

With a focus on curated participation, pre-qualified networking and meaningful scientific exchange, hubXchange creates environments in which collaboration can lead to measurable outcomes.

For more information about the San Francisco Life Science Roundtable Series 2026, including the latest agendas, industry experts and registration details, visit: https://hub-xchange.com/

Media Contact: Nathan Merryfield (Nathan@hub-xchange.com)